PMC:7216762 / 7230-7785 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T6","span":{"begin":26,"end":34},"obj":"Body_part"},{"id":"T7","span":{"begin":205,"end":213},"obj":"Body_part"},{"id":"T8","span":{"begin":264,"end":273},"obj":"Body_part"},{"id":"T9","span":{"begin":298,"end":311},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma9825"}],"text":"Tocilizumab, a monoclonal antibody developed for treating rheumatoid arthritis, was first used to treat some COVID-19 patients in Naples. It inhibits the receptor of IL-6, likely damping the effect of the cytokine storms (i.e., massive release of pro-inflammatory cytokines that overstimulates the immune system) observed in more severe cases. Today, AIFA swiftly authorized the beginning of a clinical trial,6 involving many hospitals in Italy, that was made possible also by Roche committing to supply the drug for free for the whole emergency duration."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T6","span":{"begin":298,"end":311},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"}],"text":"Tocilizumab, a monoclonal antibody developed for treating rheumatoid arthritis, was first used to treat some COVID-19 patients in Naples. It inhibits the receptor of IL-6, likely damping the effect of the cytokine storms (i.e., massive release of pro-inflammatory cytokines that overstimulates the immune system) observed in more severe cases. Today, AIFA swiftly authorized the beginning of a clinical trial,6 involving many hospitals in Italy, that was made possible also by Roche committing to supply the drug for free for the whole emergency duration."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T20","span":{"begin":58,"end":78},"obj":"Disease"},{"id":"T21","span":{"begin":69,"end":78},"obj":"Disease"},{"id":"T22","span":{"begin":109,"end":117},"obj":"Disease"}],"attributes":[{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0008383"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005578"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Tocilizumab, a monoclonal antibody developed for treating rheumatoid arthritis, was first used to treat some COVID-19 patients in Naples. It inhibits the receptor of IL-6, likely damping the effect of the cytokine storms (i.e., massive release of pro-inflammatory cytokines that overstimulates the immune system) observed in more severe cases. Today, AIFA swiftly authorized the beginning of a clinical trial,6 involving many hospitals in Italy, that was made possible also by Roche committing to supply the drug for free for the whole emergency duration."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T37","span":{"begin":13,"end":14},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T38","span":{"begin":298,"end":311},"obj":"http://purl.obolibrary.org/obo/UBERON_0002405"},{"id":"T39","span":{"begin":392,"end":393},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Tocilizumab, a monoclonal antibody developed for treating rheumatoid arthritis, was first used to treat some COVID-19 patients in Naples. It inhibits the receptor of IL-6, likely damping the effect of the cytokine storms (i.e., massive release of pro-inflammatory cytokines that overstimulates the immune system) observed in more severe cases. Today, AIFA swiftly authorized the beginning of a clinical trial,6 involving many hospitals in Italy, that was made possible also by Roche committing to supply the drug for free for the whole emergency duration."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T10","span":{"begin":166,"end":168},"obj":"Chemical"},{"id":"T12","span":{"begin":508,"end":512},"obj":"Chemical"}],"attributes":[{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A11","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"Tocilizumab, a monoclonal antibody developed for treating rheumatoid arthritis, was first used to treat some COVID-19 patients in Naples. It inhibits the receptor of IL-6, likely damping the effect of the cytokine storms (i.e., massive release of pro-inflammatory cytokines that overstimulates the immune system) observed in more severe cases. Today, AIFA swiftly authorized the beginning of a clinical trial,6 involving many hospitals in Italy, that was made possible also by Roche committing to supply the drug for free for the whole emergency duration."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":58,"end":78},"obj":"Phenotype"},{"id":"T2","span":{"begin":205,"end":220},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0001370"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0033041"}],"text":"Tocilizumab, a monoclonal antibody developed for treating rheumatoid arthritis, was first used to treat some COVID-19 patients in Naples. It inhibits the receptor of IL-6, likely damping the effect of the cytokine storms (i.e., massive release of pro-inflammatory cytokines that overstimulates the immune system) observed in more severe cases. Today, AIFA swiftly authorized the beginning of a clinical trial,6 involving many hospitals in Italy, that was made possible also by Roche committing to supply the drug for free for the whole emergency duration."}

{"project":"LitCovid-sentences","denotations":[{"id":"T49","span":{"begin":0,"end":137},"obj":"Sentence"},{"id":"T50","span":{"begin":138,"end":343},"obj":"Sentence"},{"id":"T51","span":{"begin":344,"end":555},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Tocilizumab, a monoclonal antibody developed for treating rheumatoid arthritis, was first used to treat some COVID-19 patients in Naples. It inhibits the receptor of IL-6, likely damping the effect of the cytokine storms (i.e., massive release of pro-inflammatory cytokines that overstimulates the immune system) observed in more severe cases. Today, AIFA swiftly authorized the beginning of a clinical trial,6 involving many hospitals in Italy, that was made possible also by Roche committing to supply the drug for free for the whole emergency duration."}

{"project":"LitCovid-PubTator","denotations":[{"id":"71","span":{"begin":166,"end":170},"obj":"Gene"},{"id":"72","span":{"begin":118,"end":126},"obj":"Species"},{"id":"73","span":{"begin":0,"end":11},"obj":"Chemical"},{"id":"74","span":{"begin":58,"end":78},"obj":"Disease"},{"id":"75","span":{"begin":109,"end":117},"obj":"Disease"}],"attributes":[{"id":"A71","pred":"tao:has_database_id","subj":"71","obj":"Gene:3569"},{"id":"A72","pred":"tao:has_database_id","subj":"72","obj":"Tax:9606"},{"id":"A73","pred":"tao:has_database_id","subj":"73","obj":"MESH:C502936"},{"id":"A74","pred":"tao:has_database_id","subj":"74","obj":"MESH:D001172"},{"id":"A75","pred":"tao:has_database_id","subj":"75","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Tocilizumab, a monoclonal antibody developed for treating rheumatoid arthritis, was first used to treat some COVID-19 patients in Naples. It inhibits the receptor of IL-6, likely damping the effect of the cytokine storms (i.e., massive release of pro-inflammatory cytokines that overstimulates the immune system) observed in more severe cases. Today, AIFA swiftly authorized the beginning of a clinical trial,6 involving many hospitals in Italy, that was made possible also by Roche committing to supply the drug for free for the whole emergency duration."}